These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
256 related articles for article (PubMed ID: 31686001)
41. A Novel NAMPT Inhibitor-Based Antibody-Drug Conjugate Payload Class for Cancer Therapy. Böhnke N; Berger M; Griebenow N; Rottmann A; Erkelenz M; Hammer S; Berndt S; Günther J; Wengner AM; Stelte-Ludwig B; Mahlert C; Greven S; Dietz L; Jörißen H; Barak N; Bömer U; Hillig RC; Eberspaecher U; Weiske J; Giese A; Mumberg D; Nising CF; Weinmann H; Sommer A Bioconjug Chem; 2022 Jun; 33(6):1210-1221. PubMed ID: 35658441 [TBL] [Abstract][Full Text] [Related]
42. Exploring alternative antibody scaffolds: Antibody fragments and antibody mimics for targeted drug delivery. Richards DA Drug Discov Today Technol; 2018 Dec; 30():35-46. PubMed ID: 30553519 [TBL] [Abstract][Full Text] [Related]
43. Recent Advances in Targeted Cancer Therapy: Are PDCs the Next Generation of ADCs? Zhang B; Wang M; Sun L; Liu J; Yin L; Xia M; Zhang L; Liu X; Cheng Y J Med Chem; 2024 Jul; 67(14):11469-11487. PubMed ID: 38980167 [TBL] [Abstract][Full Text] [Related]
44. Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy. Chen H; Lin Z; Arnst KE; Miller DD; Li W Molecules; 2017 Aug; 22(8):. PubMed ID: 28763044 [TBL] [Abstract][Full Text] [Related]
46. Targeted Delivery of Cytotoxic NAMPT Inhibitors Using Antibody-Drug Conjugates. Neumann CS; Olivas KC; Anderson ME; Cochran JH; Jin S; Li F; Loftus LV; Meyer DW; Neale J; Nix JC; Pittman PG; Simmons JK; Ulrich ML; Waight AB; Wong A; Zaval MC; Zeng W; Lyon RP; Senter PD Mol Cancer Ther; 2018 Dec; 17(12):2633-2642. PubMed ID: 30242091 [TBL] [Abstract][Full Text] [Related]
47. Physical and Chemical Stability of Antibody Drug Conjugates: Current Status. Ross PL; Wolfe JL J Pharm Sci; 2016 Feb; 105(2):391-397. PubMed ID: 26869406 [TBL] [Abstract][Full Text] [Related]
48. A DNA-Interacting Payload Designed to Eliminate Cross-Linking Improves the Therapeutic Index of Antibody-Drug Conjugates (ADCs). Miller ML; Shizuka M; Wilhelm A; Salomon P; Reid EE; Lanieri L; Sikka S; Maloney EK; Harvey L; Qiu Q; Archer KE; Bai C; Vitharana D; Harris L; Singh R; Ponte JF; Yoder NC; Kovtun Y; Lai KC; Ab O; Pinkas J; Keating TA; Chari RVJ Mol Cancer Ther; 2018 Mar; 17(3):650-660. PubMed ID: 29440292 [TBL] [Abstract][Full Text] [Related]
49. Antibody-Drug Conjugates as Cancer Therapeutics: Past, Present, and Future. Vezina HE; Cotreau M; Han TH; Gupta M J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S11-S25. PubMed ID: 28921650 [TBL] [Abstract][Full Text] [Related]
50. Design, synthesis, and biological evaluation of antibody-drug conjugates comprised of potent camptothecin analogues. Burke PJ; Senter PD; Meyer DW; Miyamoto JB; Anderson M; Toki BE; Manikumar G; Wani MC; Kroll DJ; Jeffrey SC Bioconjug Chem; 2009 Jun; 20(6):1242-50. PubMed ID: 19469529 [TBL] [Abstract][Full Text] [Related]
51. Impact of Payload Hydrophobicity on the Stability of Antibody-Drug Conjugates. Buecheler JW; Winzer M; Tonillo J; Weber C; Gieseler H Mol Pharm; 2018 Jul; 15(7):2656-2664. PubMed ID: 29809017 [TBL] [Abstract][Full Text] [Related]